The U.S. Food and Drug Administration, citing conflict of interest, has recused a member of an 11-person advisory committee set to review Biogen Inc's experimental Alzheimer's drug aducanumab on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback